The systems studied showed several coexisting mesophases, the most predominant structure being of cubic symmetry.Molecular medical imaging is intended to increase the accuracy of diagnosis, particularly in cardiovascular and cancer-related diseases, where early detection could significantly increase the treatment success rate. In this study, we present mixed micelles formed from four building blocks as a magnetic resonance imaging targeted contrast agent for the detection of atheroma and cancer cells. https://www.selleckchem.com/products/ch-223191.html The building blocks are a gadolinium-loaded DOTA ring responsible for contrast enhancement, a fibrin-specific CREKA pentapeptide responsible for targeting, a fluorescent dye and DSPE-PEG2000. The micelles were fully characterized in terms of their size, zeta potential, stability, relaxivity and toxicity. Target binding assays performed on fibrin clots were quantified by fluorescence and image signal intensities and proved the binding power. An additional internalization assay showed that the micelles were also designed to specifically enter into cancer cells. Overall, these multimodal mixed micelles represent a potential formulation for MRI molecular imaging of atheroma and cancer cells.The tumour endothelial marker 1 (TEM1/endosialin/CD248) is a receptor overexpressed in several human solid tumours and silenced in normal adult tissues, representing a suitable and potentially safe target for radioimmunotherapy of sarcoma. To develop new tools with improved TEM1 targeting properties, a new panel of antibody fragments was for the first time evaluated preclinically following 125I radiolabelling. The antibody fragment 1C1m-Fc, with the highest human/murine TEM1 binding affinity, was extensively characterized in vitro and in vivo in a Ewing's sarcoma human xenograft mouse model. In silico studies were also performed to elucidate the influence of a single amino acid mutation in the complementarity-determining region (CDR3) of the heavy chain, upon affinity maturation of the parental clone 1C1-Fc. From this study, 1C1m-Fc emerged as a promising candidate for the development of TEM1-targeted radioimmunoconjugates, namely to be further explored for theranostic applications with other suitable medical radionuclides. Bertholletia excelsa is a rich herbal source of anti-oxidants and phenols. The goal of this study is to evaluation the effect of bertholletia excelsa nut on body weight, C-reactive protein (CRP) and lipid profile. A literature search was conducted in PubMed, Scopus and Web of sciences databases by two reviewers up to October 2019. Random effect model used to combine results. Six studies included in analysis with 71 participants. The population was public population. Pooled results showed Bertholletia excelsa have reduction effect on triglyceride weighted mean difference (WMD -8.23 mg/dl, 95 % CI -15.09, -1.38, I² = 0%), Cholesterol (WMD -14.31 mg/dl, 95 % CI -23.38, -5.24, I² = 47 %), Low-density lipoprotein (LDL) (WMD -9.27 mg/dl, 95 % CI -13.48, -5.06, I² = 0%). This study provided an evidence that Bertholletia excelsa nuts have reduction effect on triglyceride, cholesterol, and LDL levels. This study provided an evidence that Bertholletia excelsa nuts have reduction effect on triglyceride, cholesterol, and LDL levels. Randomized clinical trials (RCTs) examining the effects of resveratrol supplementation on liver enzymes in non-alcoholic fatty liver disease (NAFLD) have reported conflicting results. The aim of this systematic review was to summarize evidence of the effects of resveratrol supplementation on alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels in patients with NAFLD by performing a meta-analysis of RCTs. PubMed, Cochrane Library, Scopus, and Web of Science databases were electronically explored from inception to August 2020 for all relevant studies. Random effect models were used to estimate liver enzymes changes between resveratrol supplementation and control groups by evaluating the weighted mean differences (WMD) with 95 % confidence intervals (CIs). Five trials with a total of 216 patients were included in the meta-analysis. The pooled results showed that resveratrol supplementation did not result in significant changes in serum ALT (WMD= -2.48 IU/L; 95 % CI -12.30, 7.34; P = 0.62), and AST (WMD = -2.90 IU/L; 95 % CI -9.77, 3.98; P = 0.40) concentrations. Subgroup analysis revealed a significant reduction in serum ALT and AST concentrations in the participants with mean age <45 years, and studies with intervention dosage <1000 mg/day. In addition, ALT and AST levels were decreased significantly in studies with duration >12 weeks and participants with BMI < 30 kg/m , respectively. The overall results indicated that resveratrol supplementation did not affect liver enzymes in patients with NAFLD. More studies examining the effect of resveratrol supplementation on liver enzymes are needed in the future. The overall results indicated that resveratrol supplementation did not affect liver enzymes in patients with NAFLD. More studies examining the effect of resveratrol supplementation on liver enzymes are needed in the future. The aim of this study was to evaluate the effect of hypocaloric high-protein, low-carbohydrate weight loss diet supplemented with fennel on anthropometric and androgen indices in overweight and obese women with polycystic ovary syndrome (PCOS). A randomized controlled trial with a factorial design was performed on sixty-four overweight/obese women with PCOS. Participants were randomly allocated to four groups (n = 16 per group) as follows 1) hypocaloric standardize diet + fennel (2 capsule/day) (HSDF), 2) hypocaloric high-protein diet + fennel (2 capsule/day) (HHPF), 3) hypocaloric standardize diet + placebo (HSDP), and 4) hypocaloric high-protein diet + placebo (HHPP). The mean (SD) age of the participants was 28.54 (6.80) years and body mass index was 32.24 (4.65) kg/m . At the end of intervention, protein intake was 20.43 % in the groups that received a high-protein diet versus 16.37 % in the standard diet groups (P < 0.001). Combination of hypocaloric high-protein diet and fennel capsule did not significantly affect change in outcomes compared with groups not receiving them.